Adaptive Biotechnologies CorporationADPTNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +3.66% | +25.24% | +36.33% | +102.38% | +51.04% |
| Gross Profit Growth | +12.40% | +48.87% | +71.24% | +154.69% | +81.74% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.52% | +2.34% | +3.17% | +3.33% | +4.10% |
| Weighted Average Shares Diluted Growth | +1.52% | +2.34% | +3.17% | +10.61% | +4.10% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +9.91% | +3.72% | +24.36% | +13.49% | +20.69% |
| Inventory Growth | -41.58% | -34.66% | -36.41% | -16.91% | +16.35% |
| Asset Growth | -18.42% | -17.65% | -15.09% | -12.16% | -4.94% |
| Book Value per Share Growth | -35.25% | -32.32% | -27.90% | -11.59% | +3.69% |
| Debt Growth | -9.50% | -9.94% | -10.41% | -10.91% | +213.90% |
| R&D Expense Growth | -19.32% | -19.98% | -4.81% | -2.04% | -6.16% |
| SG&A Expenses Growth | -7.04% | -3.51% | +8.24% | +9.57% | +11.12% |